sickle cell disease

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Summary: 
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa

OLON Continues Strategic Collaboration With Novartis, Supporting the Expansion of the Africa Sickle Cell Disease Program to Kenya, Uganda and Tanzania

Press Release

October 1, 2020 /3BL Media/ - OLON announced it will continue its collaboration with Novartis to support the Africa Sickle Cell Disease program as it expands to Kenya, Uganda and Tanzania.  Initially launched in 2019 by Novartis and its partners in Ghana, the Africa Sickle Cell Disease program intends to improve the lives of people with sickle cell disease and accelerate access to treatment and related laboratory tests.

Relief From Sickle Cell Disease Made Possible by Red Cross and FedEx

Blog

If you could, with relative ease, relieve someone else’s physical suffering from an agonizing blood disorder, would you?

Novartis Expands Africa Sickle Cell Disease Program to Uganda and Tanzania

Summary: 
  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1
Press Release
  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1

Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis

Summary: 
  • Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
  • Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
  • Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
  • 15 000 babies are born with sickle cell disease every year in Ghana2
Press Release
  • Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
  • Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
  • Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
  • 15 000 babies are born with sickle cell disease every year in Ghana2

Uncovering Sickle Cell Disease

Article

Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3

Meet Amgen Scholars Alumni Assama Ketegou

"I felt a sense of community among my peers in the Amgen Scholars Program. Everyone was in the same boat, trying to figure out what they wanted to do for careers."
Blog

Host University: Washington University in St. Louis

Home University: New York University

Amgen Scholar Year: 2016

Major: Pre-medicine

Expected Graduation:2017

Journey to Science

How did you become interested in science?

Subscribe to sickle cell disease